Trial Profile
Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PEBEL
- 22 Jun 2023 Planned End Date changed from 31 Dec 2023 to 30 Sep 2024.
- 22 Jun 2023 Planned primary completion date changed from 31 May 2023 to 31 Oct 2023.
- 22 Jun 2023 Status changed from recruiting to active, no longer recruiting.